Anderson Devon E, Robinson Katlyn S, Wiedrick Jack, Crawford Dennis C
Department of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland, Oregon, USA.
Biostatistics and Design Program, Oregon Health & Science University, Portland, Oregon, USA.
Orthop J Sports Med. 2018 Nov 15;6(11):2325967118805441. doi: 10.1177/2325967118805441. eCollection 2018 Nov.
Osteochondral allograft (OCA) transplantation has become a standard therapy for cartilage restoration in young patients.
To determine the efficacy of fresh OCA transplantation for focal cartilage lesions in patients aged ≥40 years compared with a group of patients aged ≤39 years.
Cohort study; Level of evidence, 3.
A database was used to identify patients who underwent fresh OCA transplantation in the knee in a single-surgeon practice over a 10-year period and who completed baseline patient-reported outcome (PRO) questionnaires, including the International Knee Documentation Committee (IKDC); Knee injury and Osteoarthritis Outcome Score (KOOS) subscales of Pain, Symptoms, Activities of Daily Living, Quality of Life (QOL), and Sports & Recreation; and Veterans RAND 12-Item Health Survey (VR-12). Patients who completed the same PRO measures at a minimum 12-month follow-up were categorized into 2 groups based on age at surgery and were observed longitudinally. Mixed-model regression was used to predict longitudinal growth curves for each PRO score while controlling for confounding patient and surgical variables.
The study group consisted of 38 patients with a mean age of 52.32 years (range, 40-69 years) and mean final follow-up of 44.47 ± 24.32 months. The control group consisted of 42 patients with a mean age of 27.19 years (range, 15-39 years) and mean final follow-up of 33.75 ± 19.53 months. A statistically significant improvement from baseline to final follow-up was seen for the IKDC score and all 5 KOOS subscores in both the study and the control groups ( < .01 in 10 of 12 comparisons and < .05 for the other 2 comparisons). Maximum improvements were seen in the KOOS QOL and Sports & Recreation subscores for both groups. There was no statistically significant difference between groups in the change from baseline to final follow-up or in differences at any time point in model-based longitudinal projections for any PRO score through 5 years.
There was a significant improvement of outcomes for both groups, with no statistically significant difference between groups over longitudinal follow-up. The efficacy of fresh OCA transplantation in adults aged ≥40 years with a focal chondral lesion and without osteoarthritis is similar to that of younger adults, and benefits are greatest for the KOOS QOL and Sports & Recreation subscales, which reflect functional outcomes.
骨软骨异体移植(OCA)已成为年轻患者软骨修复的标准治疗方法。
确定年龄≥40岁的患者与年龄≤39岁的患者相比,新鲜OCA移植治疗局限性软骨损伤的疗效。
队列研究;证据等级,3级。
使用一个数据库来识别在10年期间由单一外科医生实施膝关节新鲜OCA移植且完成了包括国际膝关节文献委员会(IKDC)在内的基线患者报告结局(PRO)问卷的患者;膝关节损伤和骨关节炎结局评分(KOOS)的疼痛、症状、日常生活活动、生活质量(QOL)以及运动与娱乐亚量表;以及退伍军人兰德12项健康调查(VR-12)。在至少12个月随访时完成相同PRO测量的患者根据手术时的年龄分为两组,并进行纵向观察。在控制混杂的患者和手术变量的同时,使用混合模型回归来预测每个PRO评分的纵向增长曲线。
研究组由38例患者组成,平均年龄52.32岁(范围40 - 69岁),平均最终随访时间44.47±24.32个月。对照组由42例患者组成,平均年龄27.19岁(范围15 - 39岁),平均最终随访时间33.75±19.53个月。研究组和对照组从基线到最终随访时,IKDC评分以及所有5个KOOS亚评分均有统计学显著改善(12项比较中的10项P <.01,另外2项比较P <.05)。两组在KOOS生活质量和运动与娱乐亚量表上的改善最大。从基线到最终随访的变化或在基于模型的纵向预测中5年内任何时间点的任何PRO评分的组间差异均无统计学显著意义。
两组的结局均有显著改善,在纵向随访中组间无统计学显著差异。新鲜OCA移植对于年龄≥40岁、有局限性软骨损伤且无骨关节炎的成年人的疗效与年轻成年人相似,并且对反映功能结局的KOOS生活质量和运动与娱乐亚量表的益处最大。